Matinas BioPharma Holdings Inc To Discuss EnACT Topline Data Call Transcript
Hello, and welcome to the Matinas BioPharma EnACT trial conference call and webcast. (Operator Instructions)
As a reminder, this call is being recorded. I will now turn the conference over to Peter Vozzo, Investor Relations representative for Matinas BioPharma. You may begin.
Thank you, Kevin. Good morning, everyone, and thank you for joining the Matinas BioPharma EnACT Trial Conference Call. Speaking on today's call from Matinas will be Jerry Jabbour, Chief Executive Officer; Dr. Terri Matkovits, Chief Development Officer; and Dr. Terry Ferguson, Chief Medical Officer. We also have Dr. David Boulware, Professor of Medicine, Infectious Disease and International Medicine, University of Minnesota Medical School and co-principal investigator of the EnACT trial, on the call to provide his perspectives on the data. Finally, Dr. Raphael Mannino, Chief Scientific Officer of Matinas, will also be on the call and participating in the question-and-answer session.
For those of you participating via conference
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |